| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016530345 |
| P356 | DOI | 10.1038/BMT.2015.335 |
| P8608 | Fatcat ID | release_66f7d3n4j5d5npel55jjirdpmq |
| P932 | PMC publication ID | 9644293 |
| P698 | PubMed publication ID | 26878658 |
| P50 | author | Hamid Bassiri | Q87295583 |
| P2093 | author name string | R Das | |
| N P Patel | |||
| P Guan | |||
| K E Nichols | |||
| P2860 | cites work | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial | Q84401841 |
| Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation | Q84595134 | ||
| The role of NKT cells in tumor immunity | Q24648939 | ||
| Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications | Q24685895 | ||
| Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients | Q25255724 | ||
| The immunoregulatory role of type I and type II NKT cells in cancer and other diseases | Q27027556 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides | Q28254991 | ||
| The biology of NKT cells | Q28277482 | ||
| Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A | Q28294740 | ||
| Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans | Q28511526 | ||
| iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells | Q33523809 | ||
| Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice | Q33573652 | ||
| NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. | Q34078681 | ||
| Transcriptional control of invariant NKT cell development | Q34248566 | ||
| Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency | Q34338958 | ||
| Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy | Q34431441 | ||
| Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity | Q34519826 | ||
| CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells | Q34551230 | ||
| Differential antitumor immunity mediated by NKT cell subsets in vivo | Q34603019 | ||
| Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis | Q35234774 | ||
| Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality | Q35662003 | ||
| Regulation of antitumour immunity by CD1d-restricted NKT cells | Q35798173 | ||
| T-bet concomitantly controls migration, survival, and effector functions during the development of Valpha14i NKT cells | Q35848548 | ||
| Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism | Q35866143 | ||
| IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. | Q36005345 | ||
| Signaling for NKT cell development: the SAP-FynT connection | Q36076597 | ||
| Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells | Q36096376 | ||
| Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease | Q36368026 | ||
| Pathophysiology of graft-versus-host disease | Q36368101 | ||
| Distinct functional lineages of human V(alpha)24 natural killer T cells | Q36370354 | ||
| Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining | Q36370359 | ||
| A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma | Q36370927 | ||
| A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas | Q36371124 | ||
| Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein | Q36371349 | ||
| Differential tumor surveillance by natural killer (NK) and NKT cells. | Q36375962 | ||
| Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2 | Q36399484 | ||
| A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance | Q36403071 | ||
| Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice | Q36439026 | ||
| NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d | Q36469236 | ||
| Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. | Q36713547 | ||
| The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation | Q36797263 | ||
| Control points in NKT-cell development | Q36858868 | ||
| Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease | Q37176591 | ||
| Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages | Q37209184 | ||
| Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration | Q37237496 | ||
| Type I natural killer T cells suppress tumors caused by p53 loss in mice | Q37262415 | ||
| Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation | Q37272005 | ||
| TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors | Q37291642 | ||
| The contrasting roles of NKT cells in tumor immunity | Q37312825 | ||
| Raising the NKT cell family | Q37688877 | ||
| NKT cells, Treg, and their interactions in bone marrow transplantation | Q37768104 | ||
| On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies | Q37824066 | ||
| Role of regulatory T cell populations in controlling graft vs host disease | Q37933843 | ||
| iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo . | Q39021436 | ||
| Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models | Q39622009 | ||
| Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis | Q40073092 | ||
| IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells | Q41011495 | ||
| Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells | Q42130104 | ||
| Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial | Q42323676 | ||
| Host-residual invariant NK T cells attenuate graft-versus-host immunity | Q43515226 | ||
| NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. | Q43562662 | ||
| Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells | Q46739839 | ||
| NKT cells: what's in a name? | Q47895830 | ||
| Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. | Q51022920 | ||
| A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. | Q51833179 | ||
| Shaping of iNKT cell repertoire after unrelated cord blood transplantation. | Q51887126 | ||
| Loss of IFN-gamma production by invariant NK T cells in advanced cancer. | Q52934636 | ||
| Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. | Q53518152 | ||
| Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. | Q53555765 | ||
| Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells. | Q53614939 | ||
| EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. | Q54461022 | ||
| Characterization of the immature dendritic cells and cytotoxic cells both expanded after activation of invariant NKT cells with alpha-galactosylceramide in vivo | Q56900628 | ||
| Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival | Q57217410 | ||
| Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation | Q57252638 | ||
| Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4 + and CD4 − Subset Dynamics and Correlates with Remission State | Q61048279 | ||
| Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation | Q61657682 | ||
| NKT cells are phenotypically and functionally diverse | Q62230500 | ||
| Stimulation of Host NKT Cells by Synthetic Glycolipid Regulates Acute Graft-versus-Host Disease by Inducing Th2 Polarization of Donor T Cells | Q63363303 | ||
| Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells | Q73121259 | ||
| Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15 | Q73378160 | ||
| Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells | Q73544447 | ||
| TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells | Q73662227 | ||
| Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells | Q74321466 | ||
| Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000 | Q74356047 | ||
| Critical role of NK1+ T cells in IL-12-induced immune responses in vivo | Q74463558 | ||
| Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production | Q77879159 | ||
| A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors | Q78632792 | ||
| Graft-versus-host disease in recipients of grafts from natural killer T cell-deficient (Jalpha281(-/-)) donors | Q80032701 | ||
| Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation | Q80427668 | ||
| Methods for detection, isolation and culture of mouse and human invariant NKT cells | Q80487867 | ||
| The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy | Q81164150 | ||
| Protective conditioning for acute graft-versus-host disease | Q81279975 | ||
| Alpha-galactosylceramide-driven immunotherapy for allergy | Q81350073 | ||
| Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas | Q81390839 | ||
| A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer | Q81498372 | ||
| Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load | Q81499708 | ||
| Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors | Q81803390 | ||
| Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up | Q83266186 | ||
| Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma | Q83511315 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 629-637 | |
| P577 | publication date | 2016-02-15 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression | |
| P478 | volume | 51 |
| Q52628809 | Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation. |
| Q43555934 | Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies |
| Q52776444 | Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. |
| Q52645931 | Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy. |
| Q92580247 | Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading? |
| Q52688075 | The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. |
| Q59944180 | The role of iNKT cells on the phenotypes of allergic airways in a mouse model |
| Q37632938 | γδ T Cell-Mediated Immunity to Cytomegalovirus Infection. |
Search more.